Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years

Cancer

Volumn 119, Issue 6, 2013, Pages 1140-1148

  Tevaarwerk, Amye J ^a   Gray, Robert J ^b   Schneider, Bryan P ^c   Smith, Mary Lou ^d   Wagner, Lynne I ^e   Fetting, John H ^f   Davidson, Nancy ^g   Goldstein, Lori J ^h   Miller, Kathy D ^c   Sparano, Joseph A ⁱ  

^a UNIVERSITY OF WISCONSIN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Research Advocacy Network   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

breast cancer; distant disease recurrence; distant recurrence free interval; metastatic disease; survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FLUOXYMESTERONE; GOSERELIN; HORMONE RECEPTOR; METHOTREXATE; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT RECURRENCE FREE INTERVAL; HUMAN; MAJOR CLINICAL STUDY; NEGRO; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; YOUNG ADULT;

EID: 84874725527     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27819     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Berry DA, Cronin KA, Plevritis SK, et al. Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792.
3. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH,. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010; 21: 2169-2174.
4. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN,. Is breast cancer survival improving? Cancer. 2004; 100: 44-52.
5. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007; 110: 973-979.
6. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH,. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008; 26: 4891-4898.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
8. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV,. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007; 7: 153.
9. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006; 106: 2337-2344.
10. Taylor SG 4th, Knuiman MW, Sleeper LA, et al. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 1989; 7: 879-889.
11. Taylor SG 4th, Kalish LA, Olson JE, et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985; 3: 144-154.
12. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989; 320: 485-490.
13. Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J Clin Oncol. 1998; 16: 3486-3492.
14. Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus 4 cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990; 8: 599-607.
15. Tormey DC, Gray R, Abeloff MD, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992; 10: 1848-1856.
16. Olson JE, Neuberg D, Pandya KJ, et al. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer. 1997; 79: 1138-1149.
17. Fetting JH, Gray R, Fairclough DL, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998; 16: 2382-2391.
18. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005; 23: 5973-5982.
19. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003; 349: 17-26.
20. Goldstein LJ, O'Neill A, Sparano JA, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008; 26: 4092-4099.
21. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358: 1663-1671.
22. Lin D, Sun W, Ying Z,. Nonparametric estimation of the gap time distribution for serial events with censored data. Biometrika. 1999; 86: 59-70.
23. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
24. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999; 17: 1413-1424.
25. Cortes J, O'Shaughnessy J, Loesch D, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377: 914-923.
26. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20: 2812-2823.
27. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH,. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010; 28: 92-98.
28. Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008; 19: 2012-2019.
29. Dabakuyo TS, Bonnetain F, Roignot P, et al. Population-based study of breast cancer survival in Cote d"Or (France): prognostic factors and relative survival. Ann Oncol. 2008; 19: 276-283.
30. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28: 1124-1130.
31. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23: 4265-4274.